New drugs for Parkinson's disease.
Parkinson's disease continues to be a tragic debilitator of close to half a million Americans. As more is learned about the disease, pharmacological treatment improves. Just recently, deprenyl became a part of our therapeutic armamentarium, and it appears that Sinemet CR will soon be following. It is hoped that these drugs will improve the quality and quantity of life for patients with PD until the disease can be cured.
Hodges
L C
LC
University of Arkansas for Medical Sciences, College of Nursing, Little Rock 72205.
Rapp
C G
CG
D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D002230:Carbidopa / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000523:psychology; D010627:Phenethylamines / Q000627:therapeutic use*; D011788:Quality of Life; D012642:Selegiline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000978:Antiparkinson Agents; D004338:Drug Combinations; D010627:Phenethylamines; C009265:carbidopa, levodopa drug combination; D012642:Selegiline; D007980:Levodopa; D002230:Carbidopa